Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.
Anita Wagner, PharmD
Advertisement
Articles by Anita Wagner, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Semaglutide More Than Doubled Likelihood of MASH Resolution
2
Jeff Hunnicutt to Bring Community Oncology Roots to New Role as Navista COO
3
Once-Daily Pill Zasocitinib Clears Psoriasis at Toughest Sites
4
Delgocitinib Cream Projected to Save US Health Plans Millions for Chronic Hand Eczema
5